title: Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
authors.forename: S
authors.initials: S
authors.lastname: Miyawaki
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Tanimoto
authors.forename: K
authors.initials: K
authors.lastname: Kuriyama
authors.forename: H
authors.initials: H
authors.lastname: Murakami
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: S
authors.initials: S
authors.lastname: Minami
authors.forename: K
authors.initials: K
authors.lastname: Minato
authors.forename: K
authors.initials: K
authors.lastname: Tsubaki
authors.forename: E
authors.initials: E
authors.lastname: Omoto
authors.forename: H
authors.initials: H
authors.lastname: Oh
authors.forename: I
authors.initials: I
authors.lastname: Jinnai
authors.forename: H
authors.initials: H
authors.lastname: Sakamaki
authors.forename: A
authors.initials: A
authors.lastname: Hiraoka
authors.forename: A
authors.initials: A
authors.lastname: Kanamaru
authors.forename: I
authors.initials: I
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Saito
authors.forename: T
authors.initials: T
authors.lastname: Naoe
authors.forename: O
authors.initials: O
authors.lastname: Yamada
authors.forename: N
authors.initials: N
authors.lastname: Asou
authors.forename: S
authors.initials: S
authors.lastname: Kageyama
authors.forename: N
authors.initials: N
authors.lastname: Emi
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.forename: M
authors.initials: M
authors.lastname: Tomonaga
authors.forename: R
authors.initials: R
authors.lastname: Ohno
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D011446:Prospective Studies
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine